Skip to content

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.68B+8.8%
Eli Lilly logo
Eli LillyLLY
$7.4B+168%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$5.24B-52.4%
Amgen logo
AmgenAMGN
$1.82B+5.1%
AbbVie logo
AbbVieABBV
$697M-45.9%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$69.23M-5.6%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s net income?
Oruka Therapeutics, Inc. (ORKA) reported net income of -$31.82M in Q1 2026.
How has Oruka Therapeutics, Inc.'s net income changed year-over-year?
Oruka Therapeutics, Inc.'s net income decreased by 51.5% year-over-year, from -$21M to -$31.82M.
What is the long-term trend for Oruka Therapeutics, Inc.'s net income?
Over 4 years (2021 to 2025), Oruka Therapeutics, Inc.'s net income has grown at a 52.8% compound annual growth rate (CAGR), from -$19.32M to -$105.43M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.